Celgene (CELG) Given a $112.00 Price Target by Cantor Fitzgerald Analysts
Cantor Fitzgerald set a $112.00 target price on Celgene (NASDAQ:CELG) in a research report report published on Monday. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
Other analysts have also recently issued research reports about the stock. Bank of America reaffirmed a buy rating on shares of Celgene in a report on Wednesday, September 13th. Cowen reaffirmed a buy rating and issued a $150.00 target price on shares of Celgene in a report on Tuesday, September 12th. Vetr raised shares of Celgene from a hold rating to a buy rating and set a $146.58 target price on the stock in a report on Friday, October 6th. Royal Bank of Canada reaffirmed a buy rating and issued a $173.00 target price on shares of Celgene in a report on Thursday, October 5th. Finally, Robert W. Baird reaffirmed a buy rating and issued a $162.00 target price on shares of Celgene in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $131.18.
Shares of Celgene (NASDAQ CELG) opened at $105.46 on Monday. The firm has a market cap of $83,030.00, a P/E ratio of 24.87, a P/E/G ratio of 0.68 and a beta of 1.77. Celgene has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.
Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.58 earnings per share. equities analysts forecast that Celgene will post 6.68 EPS for the current year.
A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. grew its position in Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after buying an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. grew its position in Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after buying an additional 1,610,056 shares during the last quarter. Jennison Associates LLC grew its position in Celgene by 11.5% in the 3rd quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock valued at $2,181,818,000 after buying an additional 1,546,673 shares during the last quarter. FMR LLC grew its position in Celgene by 5.9% in the 2nd quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after buying an additional 697,250 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Celgene by 3.3% in the second quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock valued at $1,439,025,000 after acquiring an additional 349,974 shares during the period. Hedge funds and other institutional investors own 79.74% of the company’s stock.
WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/celgene-celg-given-a-112-00-price-target-by-cantor-fitzgerald-analysts/1802518.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.